Abstract
Gallium-68 is a positron-emitting nuclide that has recently achieved clinical acceptance as the diagnostic radionuclide in PET tracers used for theranostic studies of lutetium-177 labeled therapeutic drugs due to the ease of access provided by germanium-68/gallium-68 generators. An alternative method of production currently being explored uses accelerators to form gallium-68 directly. This review of gallium-68 production strategies discusses available accelerator targetry at a range of beam energies and intensities, the many radiochemical separation techniques available to isolate Ga-68 from irradiated targets, isotopically enriched target material recovery, and the implications of these techniques for downstream radiolabeling applications.
Keywords: Radiochemical, PET, therapeutic molecule, gallium-68, radiochemistry, Lu-177 labeled.
Graphical Abstract
Current Radiopharmaceuticals
Title:A Review of Accelerator-Produced Ga-68 with Solid Targets
Volume: 14 Issue: 4
Author(s): Kaelyn V. Becker, Margarita Chernysheva, Todd E. Barnhart, Katherine Gagnon and Jonathan W. Engle*
Affiliation:
- Department of Medical Physics and Radiology, University of Wisconsin-Madison B1303 WIMR Cyclotron Laboratory, 1111 Highland Avenue, Madison WI 53705,United States
Keywords: Radiochemical, PET, therapeutic molecule, gallium-68, radiochemistry, Lu-177 labeled.
Abstract: Gallium-68 is a positron-emitting nuclide that has recently achieved clinical acceptance as the diagnostic radionuclide in PET tracers used for theranostic studies of lutetium-177 labeled therapeutic drugs due to the ease of access provided by germanium-68/gallium-68 generators. An alternative method of production currently being explored uses accelerators to form gallium-68 directly. This review of gallium-68 production strategies discusses available accelerator targetry at a range of beam energies and intensities, the many radiochemical separation techniques available to isolate Ga-68 from irradiated targets, isotopically enriched target material recovery, and the implications of these techniques for downstream radiolabeling applications.
Export Options
About this article
Cite this article as:
Becker V. Kaelyn , Chernysheva Margarita , Barnhart E. Todd, Gagnon Katherine and Engle W. Jonathan *, A Review of Accelerator-Produced Ga-68 with Solid Targets, Current Radiopharmaceuticals 2021; 14 (4) . https://dx.doi.org/10.2174/1874471013666201224113651
DOI https://dx.doi.org/10.2174/1874471013666201224113651 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Moving Beyond VEGF for Anti-angiogenesis Strategies in Gynecologic Cancer
Current Pharmaceutical Design Androgen Metabolic Pathway Involved in Current and Emerging Treatment for Men with Castration Resistant Prostate Cancer: Intraprostatic Androgens as Therapeutic Targets and Endocrinological Biomarkers
Current Drug Targets Systemic Approach to the Study of Complex Bone Disorders at the Whole- Genome Level
Current Genomics Persistent P21Cip1 Induction Mediates G1 Cell Cycle Arrest by Methylseleninic Acid in DU145 Prostate Cancer Cells
Current Cancer Drug Targets Subject Index to Volume 10
Current Pharmaceutical Design Novel Aspects of Neuronal Differentiation In Vitro and Monitoring with Advanced Biosensor Tools
Current Medicinal Chemistry Genes and Proteins Governing the Cellular Sensitivity to HSP90 Inhibitors: A Mechanistic Perspective
Current Cancer Drug Targets Understanding and Targeting Osteoclastic Activity in Prostate Cancer Bone Metastases
Current Molecular Medicine 9-bis[2-(pyrrolidin-1-yl)ethoxy]-6-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}-11H-indeno[1, 2-c]quinolin-11-one (BPIQ), A Quinoline Derivative Inhibits Human Hepatocellular Carcinoma Cells by Inducing ER Stress and Apoptosis
Anti-Cancer Agents in Medicinal Chemistry Flavopiridol, the First Cyclin-Dependent Kinase Inhibitor: Recent Advances in Combination Chemotherapy
Mini-Reviews in Medicinal Chemistry Brain Tumor Causes, Symptoms, Diagnosis and Radiotherapy Treatment
Current Medical Imaging Polyethylenimine as a Promising Vector for Targeted siRNA Delivery
Current Clinical Pharmacology Dual-acting of Hybrid Compounds - A New Dawn in the Discovery of Multi-target Drugs: Lead Generation Approaches
Current Topics in Medicinal Chemistry Antitumoral-Lipid-Based Nanoparticles: a Platform for Future Application in Osteosarcoma therapy
Current Pharmaceutical Design Efficacy and Safety of Nilutamide in Patients with Metastatic Prostate Cancer who Underwent Orchiectomy: A Systematic Review and Metaanalysis
Current Clinical Pharmacology Cell-in-cell phenomenon: A New Paradigm in Life Sciences.
Current Molecular Medicine Design, Synthesis and Evaluation of Quinoline-based Small Molecule Inhibitor of STAT3
Letters in Drug Design & Discovery Microwave-Assisted Multicomponent Reactions in the Heterocyclic Chemistry
Current Organic Chemistry Lipids and Their Derivatives: By-Products Used as Essential Building Blocks for Modern Drug Delivery Systems
Current Drug Targets Ghrelin, A Novel Peptide Hormone in the Regulation of Energy Balance and Cardiovascular Function
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)